Amneal Pharmaceuticals, Inc.
AMRX
$11.83
-$0.29-2.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 161.65% | 103.20% | 101.93% | 92.27% | -39.16% |
| Total Depreciation and Amortization | -5.34% | 5.94% | 8.93% | 6.19% | 2.96% |
| Total Amortization of Deferred Charges | -22.91% | -5.24% | 34.09% | 78.63% | 151.97% |
| Total Other Non-Cash Items | 50.20% | 4.93% | -34.57% | -38.25% | -36.06% |
| Change in Net Operating Assets | -4,927.43% | -713.35% | -54.57% | 13.19% | 91.38% |
| Cash from Operations | 15.21% | 4.77% | 39.06% | 52.35% | -14.61% |
| Capital Expenditure | -63.81% | -57.32% | -78.10% | -41.66% | -28.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 40.41% | 40.41% | -- | -- |
| Other Investing Activities | -5.90% | 61.37% | 70.33% | 71.18% | 34.56% |
| Cash from Investing | -78.21% | -5.39% | -13.62% | 20.95% | 8.95% |
| Total Debt Issued | 5,981.49% | 678.78% | -43.34% | -46.14% | -89.01% |
| Total Debt Repaid | -1,106.05% | -549.98% | 5.53% | -0.12% | 43.70% |
| Issuance of Common Stock | 69.84% | 48.95% | 81.84% | 149.48% | 155.88% |
| Repurchase of Common Stock | -180.16% | -189.39% | -190.42% | -195.71% | -234.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -497.84% | 33.51% | 81.76% | 91.03% | 91.48% |
| Cash from Financing | 85.11% | 67.14% | 4.58% | -2.23% | 0.37% |
| Foreign Exchange rate Adjustments | -68.17% | -3,712.07% | -312.57% | -50.40% | -1,636.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 907.19% | 1,027.25% | 152.42% | 116.87% | -69.77% |